← Back to Clinical Trials
Recruiting NCT06364644

NCT06364644 Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06364644
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Type2diabetes
Study Type INTERVENTIONAL
Enrollment 210 participants
Start Date 2025-06-20
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Community ChampionsHomegrown Heroes

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 210 participants in total. It began in 2025-06-20 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to determine whether a 6-month multilevel intervention involving problem-solving training, exercise training and support from community health workers is more effective in improving outcomes for individuals with low socioeconomic status, type 2 diabetes, obesity, and early cardiac dysfunction than receiving education and access to a community exercise facility.

Eligibility Criteria

Inclusion Criteria: * Adults from Johns Hopkins Medicine (JHM) who live in Baltimore City and adults from Johns Hopkins Community Physicians (JHCP) Hagerstown or Family Healthcare of Hagerstown who live in Washington County * Low socioeconomic status (SES) by high Area Deprivation Index (ADI) \[\>75th percentile for the state of Maryland\] plus low income) * Type 2 diabetes * Obesity (BMI≥30 kg/m\^2) Exclusion Criteria: * Age \< 30 or \>70 years * Prevalent heart failure * Uncontrolled glycemia (blood glucose \<60 mg/d or ≥ 300 mg/dl or most recent hemoglobin A1c ≥11%) * Uncontrolled blood pressure (Systolic blood pressure (SBP) ≥160 or diastolic blood pressure (DBP) ≥100 mm Hg, either on or off medications) * Known coronary artery disease (unless \< 50% stenosis by angiography) * Moderate or severe valvular heart disease * Serious medical conditions limiting life expectancy or requiring active management * Inability to participate in moderate intensity physical activity as assessed by the self-report Physical Activity Readiness Questionnaire Plus (PAR-Q+). * Any condition or planned surgery/procedure precluding exercise for ≥ 150 minutes per week * End-stage renal disease * Current participation in another behavior change program * Active alcohol or substance abuse disorder * Already engaging in regular exercise with more than 60 minutes of moderate \[3-6 METS\] to vigorous \[\>6 METS\] physical activity per week * Active pregnancy * Evidence of ischemia, dangerous arrhythmia, or other clinical instability on baseline exercise stress test

Contact & Investigator

Central Contact

Chiadi Ndumele, MD, PhD

✉ cndumel2@jhmi.edu

📞 4105022319

Principal Investigator

Chiadi Ndumele, MD, PhD

PRINCIPAL INVESTIGATOR

Johns Hopkins School of Medicine

Frequently Asked Questions

Who can join the NCT06364644 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 70 Years, studying Type2diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06364644 currently recruiting?

Yes, NCT06364644 is actively recruiting participants. Contact the research team at cndumel2@jhmi.edu for enrollment information.

Where is the NCT06364644 trial being conducted?

This trial is being conducted at Baltimore, United States, Hagerstown, United States.

Who is sponsoring the NCT06364644 clinical trial?

NCT06364644 is sponsored by Johns Hopkins University. The principal investigator is Chiadi Ndumele, MD, PhD at Johns Hopkins School of Medicine. The trial plans to enroll 210 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology